

HAVE A GAME PLAN: MANAGING POTENTIAL SIDE EFFECTS

Rubraca can cause side effects. This guide will help you work with your healthcare provider to help manage side effects that may occur during your treatment.

What is Rubraca used for?

Rubraca is a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):

- that has spread to other parts of the body, and
- has a certain type of inherited (germline) or acquired (somatic) abnormal *BRCA* gene, and you have been treated with certain medicines for your cancer.

Rubraca was approved based on response rate and how long patients' responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you.

It is not known if Rubraca is safe and effective in children.

What Warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

Please see additional Select Important Safety Information throughout this document.

Rubraca® (rucaparib) 300 mg tablets

What you can expect

Create a dosing schedule to help you remember to take your Rubraca

_____ AM

Two _____ mg tablets
in the morning

About **12** hours
after the first dose

_____ PM

Two _____ mg tablets
in the evening

Rubraca affects each person differently.

The chart below shows some of the common side effects that patients experienced while taking Rubraca.

The first 2 columns of the chart show the percentage of patients who experienced each common side effect of Rubraca. The third column represents the median number of days that patients began experiencing the side effect after starting treatment with Rubraca. Example: 62% of patients said they reported fatigue at some point during their treatment with Rubraca, and in those patients fatigue was generally first experienced 23 days after starting Rubraca.

Common side effects	% of patients	Median time before experiencing side effect
Fatigue	62%	23 Days
Nausea	52%	18 Days
Decreased red blood cell count	43%	59 Days
Changes in liver function tests	33%	16 Days
Decreased appetite	28%	30 Days
Rash	27%	45 Days
Constipation	27%	44 Days
Decreased platelet count	25%	66 Days
Vomiting	22%	43 Days
Diarrhea	20%	44 Days

Median is defined as the middle number in a group of numbers arranged from the lowest to the highest.

These are not all of the side effects of Rubraca. For more information talk to your healthcare provider.

Your oncologist may lower your dose or tell you to stop taking Rubraca for a time. This is a way to help manage side effects.

Rubraca tablets come in 3 strengths, each with its own color

300 mg

250 mg

200 mg

Images do not reflect the actual size of each tablet.

- Take tablets with or without food
- If a dose is missed take the next dose at its scheduled time
- If a dose is vomited, do not retake the dose but wait until the next scheduled time

What Warnings should I know about Rubraca? (cont'd)

If you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of Rubraca.

Please see additional Select Important Safety Information throughout this document.

Rubraca®
(rucaparib) 300 mg tablets

How you can prepare

Ask your healthcare provider for recommendations to help you manage any side effects associated with Rubraca:

Contact your healthcare provider if you experience any of the following: weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, or bruising or bleeding more easily.

Healthcare provider: _____

Phone number: _____

Please see Select Important Safety Information throughout this document.

Rubraca® (rucaparib) 300 mg tablets

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1-415-409-7220 (US toll) or 1-844-CLVS-ONC (1-844-258-7662; US toll-free).

Please see additional Select Important Safety Information throughout this document.

To learn more, please visit Rubraca.com.

CLOVIS ONCOLOGY

Rubraca® (rucaparib) 300 mg tablets